Imperiale A, Meuter L, Pacak K, Taïeb D. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors.
Semin Nucl Med 2021;
51:519-528. [PMID:
33838874 DOI:
10.1053/j.semnuclmed.2021.03.001]
[Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Management of patients with neuroendocrine neoplasms (NEN) is complex and warrants referral of these patients to high volume centers with appropriate expertise to ensure favorable outcomes. PET/CT becomes increasingly important in every step of their management and outcome. The choice of radiopharmaceutical heavily depends on tumor origin, which is intimately interconnected to embryology, grade and clinical presentation (eg, diagnostic vs theranostic settings). The aim of this review is to describe the role of SSTR, 18F-FDOPA, and 18F-FDG-PET imaging in the evaluation of NEN patients. There is emphasis on the main variants, caveats, and pitfalls that can be observed within these modalities. Nuclear physicians must be equipped with the skills to handle potential variants, caveats, and pitfalls that are commonly encountered in NEN imaging, and they should understand the expected imaging features that are encountered across various types of NENs.
Collapse